Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue factor pathway inhibitor can interact with platelets.

Takuya Nishioka1, Masaharu Yokota, Masayuki Hino

  • 1Department of Clinical and Laboratory Medicine, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno, Osaka, Japan. taku.nishioka@nifty.ne.jp

Journal of Immunological Methods
|July 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Development and implementation of a regional medical collaboration platform for hematological malignancies].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same author

Validity and Reliability of a Novel Timing Gate System for Real-Time Measurement of Sprint Force-Velocity Profile.

Journal of strength and conditioning research·2026
Same author

Determining the Minimal Number of Passive Hip and Knee Joint Movement Repetitions Recommended for the Stiff Rectus Femoris Muscle Due to Osgood-Schlatter Disease.

Children (Basel, Switzerland)·2026
Same author

Impact of CD34<sup>+</sup> cell dose on outcomes of related allogeneic PBSCT in adult AML patients.

British journal of haematology·2026
Same author

Teclistamab for multiple pulmonary lesions in extramedullary myeloma: first successful case and review of the literature.

Annals of hematology·2026
Same author

Ten-color multicolor flow cytometry-based measurable residual disease at pre-transplantation predicts relapse of acute myeloid leukemia: a prospective study.

International journal of hematology·2026
Same journal

Optimized intracellular flow cytometry panel enables CD4 and CD8 T cell cytokine profiling in Syrian hamsters.

Journal of immunological methods·2026
Same journal

Isosulfan blue sentinel lymph node biopsy enables reliable lymph node harvest and multicolor flow cytometry in mice.

Journal of immunological methods·2026
Same journal

Type-specific antibody detection of herpes simplex virus types 1&2 (HSV-1&2) in fingerstick blood at point-of-care sites by a rapid and sensitive lateral flow immunochromatographic assay.

Journal of immunological methods·2026
Same journal

Development of chimeric DGP-IgG antibodies as quality control for celiac disease diagnosis.

Journal of immunological methods·2026
Same journal

Stepwise single-cell-resolved deep immunophenotyping pipeline to characterise immune heterogeneity and functionality in health and disease.

Journal of immunological methods·2026
Same journal

Performance evaluation of Meso Scale Discovery (MSD) quantitative serological assays for detection of binding (IgG, IgA, IgM) and ACE2 inhibitory antibody levels for SARS-CoV-2.

Journal of immunological methods·2026
See all related articles

Tissue factor pathway inhibitor (TFPI) enhances platelet aggregation, contrary to previous findings suggesting it reduces platelet counts. This study shows TFPI promotes clot formation by activating platelets.

Area of Science:

  • Hematology
  • Hemostasis
  • Thrombosis

Background:

  • Tissue factor pathway inhibitor (TFPI) is a key regulator of the extrinsic coagulation cascade.
  • Previous research indicated TFPI reduces platelet counts in whole blood.
  • The interaction between TFPI and platelets remains largely unexplored.

Purpose of the Study:

  • To investigate the direct effect of TFPI on platelet aggregation.
  • To elucidate the mechanism by which TFPI influences platelet function.

Main Methods:

  • Washed human platelets were suspended in a modified Tyrode's buffer with calcium chloride.
  • Platelet aggregation was induced and measured in the presence and absence of TFPI.
  • The role of GPIIb in TFPI-mediated aggregation was assessed using anti-CD41 antibody.

Related Experiment Videos

Main Results:

  • TFPI significantly promoted platelet aggregation in washed platelets.
  • Platelet aggregation occurred without TFPI but was slower and weaker.
  • Anti-CD41 (anti-GPIIb) antibody inhibited TFPI-induced platelet aggregation, indicating GPIIb involvement.

Conclusions:

  • TFPI directly promotes platelet aggregation, suggesting a pro-thrombotic role.
  • The findings challenge previous assumptions about TFPI's effect on platelet counts.
  • TFPI's interaction with the GPIIb receptor is crucial for its platelet-aggregating activity.